A Message For Medtechs: Adapt For the Future While You Can

With the World Health Organization pressing for an inquiry into the coronavirus pandemic, it is clear that lessons must be learned for how future global public health emergencies must be handled. Medical technology has played a key role in halting the speed of the pandemic, but why has it taken an episode like COVID-19 for medtech’s true value to be recognized? ZS principal Brian Chapman says things must never go back to where they were.

Cogs

When the recriminations are over, and scientists know the chain of events that led to 5 million COVID-19 infections and 328,000 deaths in the first 20 weeks of 2020, lessons for future pandemics must be learned. They are lessons in how to cope with global public health emergencies, and in how health systems must adjust and stand in readiness for unexpected demands on their capacity to diagnose and treat.

Chinese premier Xi Jinping on 18 May opened the door ajar, albeit reluctantly, on an investigation into what happened in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

When VC Steps Back: Finding Alternative Biotech Funding

 
• By 

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By 

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

More from In Vivo

When VC Steps Back: Finding Alternative Biotech Funding

 
• By 

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By 

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By 

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.